MUCOBA Bank Plc (MUCOBA.tz) listed on the Dar es Salaam Stock Exchange under the Banking sector has released it’s 2016 interim results for the third quarter.For more information about MUCOBA Bank Plc (MUCOBA.tz) reports, abridged reports, interim earnings results and earnings presentations, visit the MUCOBA Bank Plc (MUCOBA.tz) company page on AfricanFinancials.Document: MUCOBA Bank Plc (MUCOBA.tz) 2016 interim results for the third quarter.Company ProfileMufindi Community Bank Plc (MuCoBa) offers financial products and services to residents of the Mufindi District and surrounding areas. It was the first community bank established in Tanzania and offers loans, savings accounts and other financial services to entrepreneurs, farmers and employees in Mufindi District. Formerly known as Mufindi Community Bank Limited, MuCoBa opened its doors in 1999. It was established to meet increased demand for financial services in the district assisted with the aid of a grant from a Belgium NGO, with the aim being to promote secondary education in the region. Mufindi District is an important economic hub in Tanzania which supports a strong farming community located along the Tanzam highway which passes through Mufindi and connects Dar es Salaam with Zambia and Malawi. MuCoBa services an impoverished community in a remote region who would otherwise have no or limited access to banking services. Mufindi Community Bank Plc is listed on the Dar es Salaam Stock Exchange
I’d buy cheap FTSE 100 shares in a Stocks and Shares ISA to make a million from the market crash “This Stock Could Be Like Buying Amazon in 1997” Our 6 ‘Best Buys Now’ Shares After crashing by 32% in the depths of the sell-off, The FTSE 100 index has recovered around 25% of its value. But an impressive rise in global stocks has now left many investors in fear of a second major sell-off. Regardless of whether another crash is around the corner, I’d continue to buy cheap FTSE 100 shares in an ISA and hold them for the long term. Why? Because I believe it’s the best way to build capital in the long run.Cheap FTSE 100 shares are everywhereGlancing at the FTSE 100 index, one can’t help but think there’s still significant value on offer. Many well-established and reputable companies are trading far below their average historic valuations, further indicating a wide margin of safety. Think of companies such as Royal Dutch Shell, Aviva and Barclays, whose share prices have all fallen by over 26%.5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…As always, I don’t advocate buying stocks simply because their share prices have fallen. But rather, because they’ve fallen too much. As such, these companies and many others could presently be considerably undervalued.Moreover, some of the FTSE 100’s top dividend shares are also trading on cheap valuations thanks to the sell-off. The advantage with these stocks is that they enable you to plough dividends back into your investments, fuelling the process of compounding. I’m thinking of companies such as British American Tobacco and GlaxoSmithKline that boast respective yields of 6.75% and 4.9%, and P/E ratios of 9.2 and 12.9.Investing inside a Stocks and Shares ISAThe benefits of investing inside a Stocks and Shares ISA cannot be understated in my view. Once opened, you’ll receive three tax benefits, including no tax on profits, no tax on interest earned on bonds and no tax on dividend income. These taxes can have a serious impact on your portfolio once it reaches a certain amount.You can open a Stocks and Shares ISA with numerous brokers online. It’s a simple process and can be done in a matter of minutes. Trust me, you’ll be glad you did it once you have a sizeable investment pot to your name!How to make a million from the market crashFinally, let me illustrate just how simple it actually is to make a million in the stock market. Thanks to the unmatched power of time combined with interest, you can turn a relatively small investment into a massive one.For example, let’s say you invest £375 a month in a mixture of shares in your ISA. Additionally, you manage to achieve an annual return of 9%. After exactly 35 years, your S&S ISA would have a value of £1,017,357!With that in mind, don’t miss out on the opportunity to buy cheap FTSE 100 shares in an ISA today. Hold them for the long term, and you can expect to realise some serious returns that should immensely boost your prospects of making a million. See all posts by Matthew Dumigan I’m sure you’ll agree that’s quite the statement from Motley Fool Co-Founder Tom Gardner.But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.What’s more, we firmly believe there’s still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.And right now, we’re giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool. Simply click below to discover how you can take advantage of this. Matthew Dumigan | Wednesday, 17th June, 2020 Matthew Dumigan has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Barclays. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee. Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge! Image source: Getty Images. I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement. Enter Your Email Address
As the FTSE 100 climbs in December, here’s why I think it’s still cheap See all posts by Alan Oscroft Markets around the world are reeling from the coronavirus pandemic…And with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be daunting prospect during such unprecedented times.Fortunately, The Motley Fool is here to help: our UK Chief Investment Officer and his analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global lock-down…You see, here at The Motley Fool we don’t believe “over-trading” is the right path to financial freedom in retirement; instead, we advocate buying and holding (for AT LEAST three to five years) 15 or more quality companies, with shareholder-focused management teams at the helm.That’s why we’re sharing the names of all five of these companies in a special investing report that you can download today for FREE. If you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio, and that you can consider building a position in all five right away. Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee. I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement. Our 6 ‘Best Buys Now’ Shares Alan Oscroft | Wednesday, 9th December, 2020 Click here to claim your free copy of this special investing report now! Simply click below to discover how you can take advantage of this. The FTSE 100 had a cracking November, gaining 689 points, or 12%. And just nine days into December, the top UK index has already climbed a further 320 points for another 5%.But these are unusual times. And this short-term success stands against the Covid-19 ravages of 2020. But are FTSE 100 share prices still good value, and what would I do now? Looking to the long term, I do think our top shares are currently undervalued. It’s hard to put many meaningful numbers on anything right now. But there is one key measure that I find increasingly valuable, and that’s the FTSE 100 index dividend yield.5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…As we entered 2020, analysts were predicting a 4.7% yield for the year. On the face of it, I think that made the index look cheap. For one thing, it’s a high yield relative to long-term levels. And, as a weighted average across all 100 shares, it covers companies not paying any dividend plus those offering small yields and reinvesting in growth instead. So picking from only those stocks considered long-term income investments, it’s possible to do significantly better than the average.Dividend valuationBut looking a bit deeper, that attractive-looking 4.7% yield hid a disturbing trend. In recent years, a growing number of FTSE 100 companies have been raising their dividends faster than their earnings. That means dividend cover has been falling, and I don’t see that as a very prudent approach. It makes future dividends potentially less reliable, and diminishes a company’s ability to weather any financial storms coming along in the future. And there are always financial storms coming along in the future.Speaking of storms, nobody expected the tempest brought by the Covid-19 pandemic. But dividends have tumbled as a result, with banking dividends among the first to fall. That was at the behest of the regulator, but I reckon it was wise move anyway. I do think the FTSE 100 banks were getting a little ahead of themselves in providing progressive dividends. Even though they were passing the Bank of England’s stress tests comfortably, there wasn’t much cover kept in reserve to cope with, for example, further Brexit weakness.FTSE 100 in 2021?The overall result has been a big drop in the anticipated FTSE 100 index dividend yield. Forecasts now suggest something around the 3.2% mark this year. And as share prices strengthen, so yields fall further. But what is my long-winded explanation saying about my take on the valuation of our top shares?Well, the 2020 dividend downturn is surely only temporary. The banks will be keen to get back to paying out the annual cash. A good few other companies have not suffered as badly as they might, and we will presumably see their dividends coming back too.So I expect the FTSE dividend yield in 2021 to be nicely ahead of 2020. I do hope we see a more conservative approach in the future. But I can easily see an overall yield approaching the 4% mark. On that assumption, I think the FTSE 100 is undervalued. I’m buying. Views expressed in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Enter Your Email Address 5 Stocks For Trying To Build Wealth After 50 Image source: Getty Images.
Share on Facebook Tweet on Twitter Dunkin’ Donuts is welcoming back one of fall’s favorite flavors with pumpkin coffees and baked goods. The pumpkin flavored goodies returned Aug 29th.In addition to classic pumpkin, Dunkin’ Donuts will offer a new way for coffee lovers to satisfy fall flavor cravings, introducing salted caramel flavored coffee, lattes and macchiatos, available for a limited time. Served hot or iced, salted caramel flavored coffees combine sweet and salty in a delicious blend for the cooler months.Dunkin’ Donuts also announced that almond milk will now be available at all restaurants nation-wide as a non-dairy alternative. Through a partnership with Blue Diamond Growers, Dunkin’ Donuts first introduced Blue Diamond Vanilla Almond Breeze almond milk at the majority of its restaurants in 2014 as an addition to hot or iced coffee and espresso beverages.Dunkin’ Donuts’ entire autumn array offers one of the largest varieties of pumpkin choices of any national restaurant chain, available all day long. Guests can savor the season with Dunkin’ Donuts’ delicious pumpkin flavored coffee and lattes, served hot or iced. Dunkin’ Donuts’ pumpkin macchiato, also served hot or iced, is a handcrafted, layered espresso beverage made with steamed milk and pumpkin flavored swirl, topped with a double shot of Dunkin’ Donuts’ rich, freshly-brewed espresso.Dunkin’ Donuts will also bring back baked goods perfect for a fall treat any time of day, including the pumpkin donut, a glazed pumpkin cake donut that can also be enjoyed as bite-size MUNCHKINS® donut hole treats. Dunkin’ Donuts’ pumpkin muffin is a pumpkin spiced autumn delight topped with white icing and sweet streusel crumbs.For fall brew-at-home options, Dunkin’ Donuts pumpkin flavored K-Cup® pods are available in a box of 14 individually-sized portions, and Dunkin’ Donuts’ packaged pumpkin flavored coffee is available in a 16 ounce size. Both are available at participating Dunkin’ Donuts restaurants, as well as online at http://shop.dunkindonuts.com. For a new fall treat, Dunkin’ Donuts has introduced new Pumpkin Spice packaged coffee and K-Cup® pods (in both 10-count and 16-count boxes), available at grocery stores nationwide for a limited time only. TAGSDunkin’ DonutsPumkin Previous articleA Bird, A Man…and a fishing rodNext article5 of the Most Common Football Injuries Dale Fenwick RELATED ARTICLESMORE FROM AUTHOR The Anatomy of Fear Free webinar for job seekers on best interview answers, hosted by Goodwill June 11 LEAVE A REPLY Cancel reply Please enter your comment! Please enter your name here You have entered an incorrect email address! Please enter your email address here Support conservation and fish with NEW Florida specialty license plate Save my name, email, and website in this browser for the next time I comment.
Top of the News Name (required) Mail (required) (not be published) Website EVENTS & ENTERTAINMENT | FOOD & DRINK | THE ARTS | REAL ESTATE | HOME & GARDEN | WELLNESS | SOCIAL SCENE | GETAWAYS | PARENTS & KIDS 81 recommended0 commentsShareShareTweetSharePin it Kevin M. O’SullivanSouthern California-based law firm Hahn & Hahn LLP announced today that seasoned corporate attorney Kevin M. O’Sullivan has joined the firm’s Business Department.“As the complexities of the marketplace continue to grow for our business clients, we continue to expand to meet their needs,” said Managing Partner Christianne Kerns. “Kevin’s deep experience will be a tremendous resource to our clients.”O’Sullivan represents business entities in all aspects of corporate and business law, including mergers and acquisitions, venture capital financing, public and private placements of securities, and securities regulation. He has represented companies in various industries in the structuring, negotiating, and drafting of corporate transaction documents.“Hahn & Hahn has a strong reputation in Southern California, and I am looking forward to working with an exceptional team of lawyers and professionals,” said O’Sullivan.O’Sullivan earned his bachelor’s degree from UC Berkeley and JD from the University of Michigan Law School. A native Angeleno, O’Sullivan started his career practicing corporate law with Paul Hastings LLP in downtown Los Angeles, where he spent nearly eight years. Most recently, O’Sullivan served in the role of associate general counsel with TeamHealth, a national healthcare company, out of its Los Angeles office, a position that he held for the past five and half years.Hahn & Hahn LLP has been an active member of the Southern California business and legal communities since 1899. For more information visit https://www.hahnlawyers.com/ Your email address will not be published. Required fields are marked * Business News Hahn & Hahn Bolsters Corporate Team STAFF REPORT Published on Tuesday, August 11, 2020 | 11:38 am Business News Community News Subscribe faithfernandez More » ShareTweetShare on Google+Pin on PinterestSend with WhatsApp,Darrel Done BusinessVirtual Schools PasadenaHomes Solve Community/Gov/Pub SafetyPASADENA EVENTS & ACTIVITIES CALENDARClick here for Movie Showtimes More Cool Stuff CITY NEWS SERVICE/STAFF REPORT Pasadena Will Allow Vaccinated People to Go Without Masks in Most Settings Starting on Tuesday HerbeautyWant To Seriously Cut On Sugar? You Need To Know A Few TricksHerbeautyHerbeautyHerbeautyShort On Time? 10-Minute Workouts Are Just What You NeedHerbeautyHerbeautyHerbeautyStop Eating Read Meat (Before It’s Too Late)HerbeautyHerbeautyHerbeautyTop 9 Predicted Haircut Trends Of 2020HerbeautyHerbeautyHerbeauty10 Secrets That Eastern Women Swear By To Stay Young LongerHerbeautyHerbeautyHerbeautyThe Most Heartwarming Moments Between Father And DaughterHerbeautyHerbeauty STAFF REPORT Pasadena’s ‘626 Day’ Aims to Celebrate City, Boost Local Economy Make a comment STAFF REPORT First Heatwave Expected Next Week Get our daily Pasadena newspaper in your email box. Free.Get all the latest Pasadena news, more than 10 fresh stories daily, 7 days a week at 7 a.m. Community News Home of the Week: Unique Pasadena Home Located on Madeline Drive, Pasadena
TAGSAnti Austerity AllianceCllr Cian PrendivilleKieran Lehanelead pipeslimerickLimerick City and County Council Director of services, Kieran LehaneLIMERICK City and County Council say it is difficult to be precise as to the exact location and number of remaining lead connections.Anti-Austerity Alliance councillor Cian Prendiville submitted a question to the Council asking where lead pipes are still in use, both in houses and estates built by the city and county councils and the private houses approved by them?Sign up for the weekly Limerick Post newsletter Sign Up In response, director of services, Kieran Lehane explained, “Public water supplies were traditionally delivered through cast iron mains with lead pipe connections from the mains to properties. This practice was phased out gradually from the 1950s onwards. Accordingly it is likely that properties connected to mains before this time would have utilised lead services.”Mr Lehane pointed out that Limerick City and County Council has replaced almost 2,000 of these lead services in the last number of years in areas such as Janesboro, Pennywell, Garryowen, Kilalee, Hyde Road, Prospect, Upper and Lower Carey’s Road, Lansdowne Park, New Road, Brown’s Quay and O’Dwyer’s Villas in Thomondgate and Rathbane.He also confirmed that Irish Water is now embarking on a programme to replace lead services in Ballynanty, Kileely and St Mary’s Park.“Over the years the Council would also have replaced lead services when carrying out repairs/refurbishment and redevelopment to houses in its housing stock. In addition to this many households would have replaced lead connections themselves,” said Mr Lehane.“Accordingly its difficult to be precise as to the exact location and number of remaining lead connections. Work being carried out by Irish Water at present will inform this process and provide a more accurate assessment of remaining lead services,” he concluded. Predictions on the future of learning discussed at Limerick Lifelong Learning Festival RELATED ARTICLESMORE FROM AUTHOR Advertisement NewsLocal NewsCouncil difficulty finding lead pipes in LimerickBy Alan Jacques – September 25, 2014 1063 Twitter Linkedin Email Facebook Vanishing Ireland podcast documenting interviews with people over 70’s, looking for volunteers to share their stories WhatsApp WATCH: “Everyone is fighting so hard to get on” – Pat Ryan on competitive camogie squads Limerick Ladies National Football League opener to be streamed live Print Limerick’s National Camogie League double header to be streamed live Previous articleMoses gets behind Limerick’s Urban RunNext articleDominicans depart after 800 years Alan Jacqueshttp://www.limerickpost.ie Limerick Artist ‘Willzee’ releases new Music Video – “A Dream of Peace”
Local NewsBusiness Facebook Previous articleIndonesian volcano unleashes river of lava in new eruptionNext articleShift4 Payments Launches Shift4Shop eCommerce Solution Digital AIM Web Support Neurophth Therapeutics Further Expands Ocular Gene Therapy Expertise with Appointment of Qiutang Li, Ph.D., as Chief Scientific Officer By Digital AIM Web Support – January 27, 2021 Pinterest WhatsApp Twitter TAGS WhatsApp WUHAN, China and NEWARK, Del., Jan. 27, 2021 /PRNewswire/ — Wuhan Neurophth Biotechnology Ltd., a fully-integrated genetic medicines company developing AAV-delivered gene therapies for the treatment of ocular diseases, today announced the appointment of Qiutang Li, Ph.D., as Chief Scientific Officer. She will be mainly responsible for the company’s global R&D, IND portfolio strategy, and the establishment of a highly-effective platform to allow for the exchange of cross-discipline information. Dr. Li has over 30 years of experience in basic and applied biomedical research. She joins Neurophth from the University of Louisville School of Medicine, where she was a professor in the department of Ophthalmology and Visual Sciences for over 14 years. Her research focuses on the role of Hippo/YAP1 signaling pathway on different stages of ocular development, NF-kB/IKK2 inhibition of neovascularization, and gene discovery screening for eye diseases using mouse models. Throughout her career, Dr. Li has contributed to more than 45 publications in journals including Investigative Ophthalmology & Visual Science (IOVS), Proceedings of the National Academy of Sciences of the United States of America (PNAS), Nature Review Immunology, and Science. She is currently the editorial board member of Scientific Reports and Source Journal of Ophthalmology. Dr. Li holds a Ph.D. in cell biology from the Washington University in St. Louis and obtained both her Bachelor’s and Master of Science degrees in Genetics from Beijing University. “We are thrilled to have Dr. Li on our team, bringing over 3 decades of her diverse experience in basic and applied biomedical research,” said Bin Li, M.D., Ph.D., Founder and Chairman of the Board of Neurophth. “Given her prior experience at Baylor College of Medicine mentored by Dr. Savio Woo, an internationally recognized expert in molecular human genetics and gene therapy, and Dr. Mark Kay, a leading researcher in the fields of AAV gene therapy and the current Head of Division of Human Gene Therapy at the Stanford University School of Medicine, Dr. Li has extensive knowledge in gene therapy for hepatic deficiencies, ocular diseases, and viral vector reconstruction.” “We are excited to have Qiutang join and expand our exceptional research and development team. She brings a wealth of experience in gene therapies for ocular diseases to Neurophth,” said Alvin Luk, Ph.D., M.B.A., C.C.R.A., Chief Executive Officer at Neurophth. “Her deep understanding of viral vector design and animal models in the inhibition of neovascularization for ocular diseases, such as age-related macular degeneration and diabetic retinopathy, further bolsters our ability to deliver on our growing pipeline of clinical programs and platform capabilities.” “It has been captivating to watch the scale, scope, and speed with which Neurophth has successfully transformed itself into an innovative and diversified gene therapy company,” said Dr. Li. “I look forward to being a part of Neurophth team as the company executes the next stage of its growth strategy and expands its pipeline of gene therapy candidates focused on ocular and non-ocular diseases, building a brighter future for patients worldwide.” About Neurophth Neurophth is China’s first gene therapy company in ophthalmic diseases. Headquartered in Wuhan with subsidiaries in Shanghai, Suzhou, and the U.S., Neurophth, a fully integrated company, is striving to discover and develop gene therapies for patients suffering from blindness and other eye diseases globally. Our AAV validated platform which has been published in Nature – Scientific Reports, Ophthalmology, and EBioMedicine, successfully delivered proof-of-concept data with investigational gene therapies in the retina. Our most advanced investigational candidate, NR082 (rAAV2-ND4), in development for the treatment of ND4-mutated LHON, has received orphan drug designations in the U.S. The pipeline also includes ND1-mutated LHON, autosomal dominant optic atrophy, glaucoma, wAMD/DME, and other preclinical candidates. Neurophth has initiated the scaling up in-house process in single-use manufacturing technologies to support future commercial demand at the Suzhou facility. To learn more about us and our growing pipeline, visit www.neurophth.com. View original content to download multimedia: http://www.prnewswire.com/news-releases/neurophth-therapeutics-further-expands-ocular-gene-therapy-expertise-with-appointment-of-qiutang-li-phd-as-chief-scientific-officer-301215834.html SOURCE Neurophth Therapeutics, Inc. Pinterest Facebook Twitter
Top Stories[Article 113 Limitation Act] Limitation Period Begins To Run When The Right To Sue Accrues And Not When It ‘First’ Accrues: SC LIVELAW NEWS NETWORK5 Jun 2020 7:35 AMShare This – x In cases governed by Article 113 of the Limitation Act, the period of limitation begins to run “when the right to sue accrues” and not when the right to sue “first” accrues, the Supreme Court has observed The suit was filed by the plaintiff against his bank praying for a decree for rendition of true and correct accounts in respect of the interest/commission charged and deducted by…Your free access to Live Law has expiredTo read the article, get a premium account.Your Subscription Supports Independent JournalismSubscription starts from ₹ 599+GST (For 6 Months)View PlansPremium account gives you:Unlimited access to Live Law Archives, Weekly/Monthly Digest, Exclusive Notifications, Comments.Reading experience of Ad Free Version, Petition Copies, Judgement/Order Copies.Subscribe NowAlready a subscriber?Login In cases governed by Article 113 of the Limitation Act, the period of limitation begins to run “when the right to sue accrues” and not when the right to sue “first” accrues, the Supreme Court has observed The suit was filed by the plaintiff against his bank praying for a decree for rendition of true and correct accounts in respect of the interest/commission charged and deducted by the defendant Bank relating to his current account for the period between 1.4.1997 and 31.12.2000 and also for recovery of the excess amount charged by the Bank consequent to rendition of accounts with interest at the rate of 18% per annum from the date of deduction including interest pendente lite realization of the amount and future interest. The plaint was rejected by the Trial Court under Order VII Rule 11(d) of the CPC on the ground that it was barred by law of limitation, as it was filed beyond the period of three years prescribed in Article 113 of the Limitation Act, from the date when the right to sue accrued to the appellant in October, 2000. This order of the Trial Court was upheld by the First Appellate Court and the High Court. The issue before the Apex Court was whether the plaint could have been rejected by invoking Order VII Rule 11(d) of the CPC? Referring to the averments in the plaint, the bench comprising of Justices AM Khanwilkar, Indira Banerjee and Dinesh Maheshwari noted many correspondences the plaintiff had made with the bank on many dates. The court, therefore, proceeded to discuss the scope of Article 113 of the Limitation Act. It said: “Concededly, the expression used in Article 113 is distinct from the expressions used in other Articles in the First Division dealing with suits such as Article 58 (when the right to sue “first” accrues), Article 59 (when the facts entitling the plaintiff to have the instrument or decree cancelled or set aside or the contract rescinded “first” become known to him) and Article 104 (when the plaintiff is “first” refused the enjoyment of the right). The view taken by the trial Court, which commended to the first appellate Court and the High Court in second appeal, would inevitably entail in reading the expression in Article 113 as – when the right to sue (first) accrues. This would be rewriting of that provision and doing violence to the legislative intent. We must assume that the Parliament was conscious of the distinction between the provisions referred to above and had advisedly used generic expression “when the right to sue accrues” in Article 113 of the 1963 Act. Inasmuch as, it would also cover cases falling under Section 22 of the 1963 Act, to wit, continuing breaches and torts.” The bench referred to two earlier decisions: Union of India & Ors. vs. West Coast Paper Mills Ltd. & Anr (2004) 2 SCC 747 and Khatri Hotels Private Limited & Anr. Vs. Union of India (2011) 9 SCC 126. Examining the plaint, the bench said that the fact that the plaintiff had eventually sent a legal notice on 28.11.2003 and again on 7.1.2005 and then filed the suit on 23.2.2005, is also invoked as giving rise to cause of action. The appeal was therefore allowed by setting aside the judgments of the High Court, First Appellate Court and the Trial Court.Case no.: CIVIL APPEAL NO. 2514 OF 2020 Case name: Shakti Bhog Food Industries Ltd. Vs. The Central Bank of IndiaCoram: Justices AM Khanwilkar, Indira Banerjee and Dinesh Maheshwari Counsel: Advocates Nischal Kumar Neeraj and Anuj JainClick here to Read/Download JudgmentRead JudgmentSubscribe to LiveLaw, enjoy Ad free version and other unlimited features, just INR 599 Click here to Subscribe. All payment options available.loading….Next Story
News UpdatesNEET Exam Postponed To September 13 & JEE To September 27 LIVELAW NEWS NETWORK3 July 2020 8:08 AMShare This – x”Keeping in mind the safety of students and to ensure quality education,” Union Cabinet Minister Dr. Ramesh Pokhriyal Nishank on Friday announced that the Joint Entrance Examinations (JEE) and the National Eligibility Cum Entrance Test (NEET) have been postponed till September. The Medical entrance examination that was initially scheduled to be held in May 2020 has been…Your free access to Live Law has expiredTo read the article, get a premium account.Your Subscription Supports Independent JournalismSubscription starts from ₹ 599+GST (For 6 Months)View PlansPremium account gives you:Unlimited access to Live Law Archives, Weekly/Monthly Digest, Exclusive Notifications, Comments.Reading experience of Ad Free Version, Petition Copies, Judgement/Order Copies.Subscribe NowAlready a subscriber?Login”Keeping in mind the safety of students and to ensure quality education,” Union Cabinet Minister Dr. Ramesh Pokhriyal Nishank on Friday announced that the Joint Entrance Examinations (JEE) and the National Eligibility Cum Entrance Test (NEET) have been postponed till September. The Medical entrance examination that was initially scheduled to be held in May 2020 has been postponed till September 13, in view of the Covid crisis. JEE Main examination will be held between September 1 and September 6, and the JEE Advanced exam will be held on September 27. The decision comes during the pendency of a petition in the Supreme Court, seeking for allocation of Test Centres for NEET in foreign countries or to postpone the examination until the COVID-19 pandemic subsists.. The petition had been filed by Advocate-on-Record Pallavi Pratap on behalf of parents of students who are applicants for the NEET UG 2020 entrance examination and reside in Doha, Qatar. Next Story
ibsky/iStock(SACRAMENTO, Calif.) — After an unidentified little girl was brought to a Sacramento fire station, authorities say they’re in contact with who they believe is the girl’s mother.A man brought the girl — nicknamed Jane Doe — to a fire station Sunday after an unknown Hispanic woman left the girl with him, according to Sacramento County Sheriff officials and Sacramento fire officials.The man knocked on the firehouse door and told the firefighters the toddler-aged girl was not his and he needed help, according to the fire department.Sheriff’s officials responded and the man was interviewed for over an hour as the toddler bonded with the firefighters in the station, according to the fire department.The girl appeared to be in good health and did not need any medical attention, according to the fire department.She was taken into the custody of Child Protective Services, Sgt. Tess Deterding of the sheriff’s office told ABC News.The Sacramento County Sheriff’s Office said Tuesday that its officers are in contact with “a woman who identified Jane DOE as her daughter” and “are working on confirming that relationship.”Copyright © 2019, ABC Radio. All rights reserved.